Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 20/20 | 0.69 |
| ▸ | MMP13 | P45452 | 4/20 | 0.68 |
| ▸ | MMP2 | P08253 | 1/20 | 0.68 |
| ▸ | MMP3 | P08254 | 1/20 | 0.68 |
| ▸ | MMP7 | P09237 | 1/20 | 0.68 |
| ▸ | MMP9 | P14780 | 1/20 | 0.68 |
| ▸ | MMP8 | P22894 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067755 | 0.97 | MMP12 (0.64) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL13144499 | 0.97 | MMP12 (0.64) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3075956 | 0.96 | MMP12 (0.62) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3085588 | 0.90 | MMP12 (0.70) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3065566 | 0.89 | MMP12 (0.66) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3073214 | 0.89 | MMP12 (0.66) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3076097 | 0.89 | MMP12 (0.66) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3088587 | 0.88 | MMP12 (0.67) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3077868 | 0.88 | MMP12 (0.64) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3077966 | 0.88 | MMP12 (0.64) | MMP12MMP13MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | claimed |
| EP-2144893-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2010-01-20 | — | — | EP | claimed |
| WO-2008137816-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-11-13 | — | — | WO | claimed |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP2, MMP12 | MMP12 3/4885MMP13 1/4885MMP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.